Trial Profile
An Open-Label, Single-Arm, Two-Stage Phase II Study Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Jul 2022
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 22 Jun 2022 Status changed from active, no longer recruiting to completed.
- 11 May 2022 Planned End Date changed from 31 Mar 2022 to 31 Mar 2023.
- 25 Jan 2020 Results (at data cut-off: 23/8/2019) safety and efficacy of cabozantinib in heavily pretreated metastatic colorectal cancer patients, presented at the 2020 Gastrointestinal Cancers Symposium.